{
  "id": 16200529,
  "title": "TG Therapeutics Announces Phase 1 Data Evaluating Azer-cel in Progressive Multiple Sclerosis in a Late-Breaking Oral Presentation at MSToronto2026",
  "url": "https://urgent.news/2026/10/23/tg-therapeutics-announces-phase-1-data-evaluating-azer-cel-in",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-10-23T15:07:31.000Z",
  "source": {
    "name": "Financial Post",
    "slug": "financial-post",
    "url": "https://financialpost.com/pmn/business-wire-news-releases-pmn/tg-therapeutics-announces-phase-1-data-evaluating-azer-cel-in-progressive-multiple-sclerosis-in-a-late-breaking-oral-presentation-at-mstoronto2026"
  },
  "original_language": "en",
  "account": null,
  "summary": "First reported clinical evaluation of an allogeneic CD19-directed CAR T-cell therapy in progressive MS demonstrated an encouraging preliminary safety profile with no high-grade CAR-T associated toxicities observed 89% of evaluable participants (16/19) had stable or improved disability scores at Day 90, despite documented progression prior to enrollment on high-efficacy therapies NEW YORK — TG…",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}